MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Prothena Corp PLC

Closed

SectorHealthcare

11.28 -6.93

Overview

Share price change

24h

Current

Min

11.08

Max

12.08

Key metrics

By Trading Economics

Income

1M

-58M

Sales

1.2M

2.1M

EPS

-1.08

Profit margin

-2,729.911

Employees

163

EBITDA

1.6M

-65M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+364.82% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

-57M

707M

Previous open

18.21

Previous close

11.28

News Sentiment

By Acuity

42%

58%

153 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Prothena Corp PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 maj 2024, 22:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

Peer Comparison

Price change

Prothena Corp PLC Forecast

Price Target

By TipRanks

364.82% upside

12 Months Forecast

Average 54.57 USD  364.82%

High 110 USD

Low 20 USD

Based on 8 Wall Street analysts offering 12 month price targets forProthena Corp PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

6

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

11.42 / 12.71Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

153 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.